Drug Trial Radar · NCT00201955
Study of Rebamipide Eye Drops to Treat Dry Eye
Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
762
Actual
Start
May 1, 2004
Primary completion
Jul 1, 2006
Study completion Jul 1, 2006
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- Collaborators
- Novartis
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca (dry eye).
Conditions
- Keratoconjunctivitis Sicca
Interventions
Rebamipide 1%Drug
ophthalmic suspension
Rebamipide 2%Drug
ophthalmic suspension
PlaceboDrug
Rebamipide-matching placebo ophthalmic suspension
Primary outcomes
What the sponsor says the trial is designed to measure.
- fluorescein corneal staining (FCS) total score at week 12 and the average primary ocular discomfort (POD) severity score at week 12Time frame: 12 week
Locations
60 sites in 1 country. Site status is shown where the registry gives one.
Harold Helms, MD
Birmingham, Alabama
Michael Bernstein, MD
Birmingham, Alabama
I Care! Eye Care!
Flagstaff, Arizona
Harvey and Bernice Jones Eye Institute
Little Rock, Arkansas
United Medical Research Institute
Inglewood, California
Benchmark Research
San Francisco, California
Southern California Clinical Research, Inc.
San Marino, California
Colorado Eye Associates, PC
Colorado Springs, Colorado
Danbury Eye Physicians and Surgeons, P.C.
Danbury, Connecticut
Florida Ophthalmic Institute
Gainesville, Florida
Florida Wellcare Alliance, L.C.
Inverness, Florida
Shettle Eye Center
Largo, Florida
Suncoast Clinical Research, Inc.
New Port Richey, Florida
Tukio Institute for Clinical Research
North Miami Beach, Florida
Magnolia Research Group, Inc.
Ocala, Florida
Radiant Research - West Palm Beach
West Palm Beach, Florida
Vision Incorporated
Savannah, Georgia
Welborn Clinic
Evansville, Indiana
Heartland Research Associates, LLC
Wichita, Kansas
Wichita Clinic, PA
Wichita, Kansas
Taustine Eye Center
Louisville, Kentucky
Bossier Optical, Inc.
Bossier City, Louisiana
Stevenson Medical Surgical Eye Center
New Orleans, Louisiana
Family Eye Centers
New Orleans, Louisiana
Ophthalmic Research Associates, Inc.
North Andover, Massachusetts
Minnesota Eye Associates
Minneapolis, Minnesota
Depremont Eye Specialists
Gulfport, Mississippi
Opthalmology Associates
Creve Coeur, Missouri
Clinical Research Laboratories
Piscataway, New Jersey
Ophthalmology Associates
Princeton, New Jersey
Eye Care Associates
Bethpage, New York
Ophthmalmic Consultants of Long Island
Lynbrook, New York
Mt. Sinai Medical Center School of Medicine
New York, New York
Ophthalmic Consultants of Long Island
New York, New York
Rochester Ophthalmological Group
Rochester, New York
Ophthalmic Consultants of Long Island
Valley Stream, New York
Western Wake Eye Center, P.A.
Cary, North Carolina
Southeast Clinical Research Associates
Charlotte, North Carolina
Horizon Eye Care - Clinical Research Dept.
Charlotte, North Carolina
Cornerstone Research Care
High Point, North Carolina
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.